Post-Endoscopy Upper Gastrointestinal Cancer in a United States Multicenter Cohort: Site- and Risk-Stratified Trends and Survival

Q: What does this research mean for the field?

Approximately 9.4% of upper gastrointestinal cancer patients experience post-endoscopy upper gastrointestinal cancer (PEUGIC) within 3 years of a non-diagnostic endoscopy, with rates and survival outcomes varying significantly by anatomical site and high-risk condition status. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Butros Fakhoury; Vinay Jahagirdar; Sachin Srinivasan; Leandro Sierra; Pojsakorn Danpanichkul; Krishan S. Patel; Cesare Hassan; Leo Alexandre; Nirav Thosani; nigel trudgill; Prateek Sharma; Madhav Desai

doi:10.1055/a-2948-3126

August 28, 2026Endoscopy

Post-Endoscopy Upper Gastrointestinal Cancer in a United States Multicenter Cohort: Site- and Risk-Stratified Trends and Survival

View Full Paper

Ask AI

Bookmark

Share

Key Points

To characterize post-endoscopy upper gastrointestinal cancer (PEUGIC) rates, longitudinal trends, and survival outcomes stratified by anatomical site and high-risk condition (HRC) status in a large US cohort.
Retrospective multicenter cohort study analyzing 14,814 patients with upper gastrointestinal cancer (UGIC) diagnosed between 2016 and 2024.
PEUGIC was defined as UGIC diagnosed 6 to 36 months after a non-diagnostic esophagogastroduodenoscopy (EGD), compared against detected UGIC diagnosed within 6 months of EGD.
Primary outcomes evaluated PEUGIC rates by cancer site (esophageal, gastric, duodenal) and HRC status; secondary outcomes evaluated 3-year overall survival using adjusted hazard ratios (aHR).
The overall PEUGIC rate was 9.4% (esophageal: 9.6%, gastric: 8.6%, duodenal: 10.7%), with significantly higher rates in patients with HRC compared to those without HRC (18.2% vs. 5.0%, P < .001).
PEUGIC was associated with improved survival compared with detected UGIC for esophageal cancer (aHR 0.82, 95% CI 0.67–0.99) and gastric cancer (aHR 0.77, 95% CI 0.62–0.96).
Among PEUGIC cases, having an HRC was associated with lower mortality compared to those without HRC for esophageal cancer (aHR 0.51, 95% CI 0.36–0.74) and gastric cancer (aHR 0.50, 95% CI 0.34–0.73).

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Retrospective cohort study reveals a 9.4% post-endoscopy cancer rate among upper GI malignancies, highlighting the need for risk-stratified quality benchmarks.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fakhoury et al. (2026) studied this question.

synapsesocial.com/papers/6a93f08e6c1a8fb52e79cbdc https://doi.org/10.1055/a-2948-3126

View Full Paper

Ask AI

Bookmark

Share

Post-Endoscopy Upper Gastrointestinal Cancer in a United States Multicenter Cohort: Site- and Risk-Stratified Trends and Survival

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Post-Endoscopy Upper Gastrointestinal Cancer in a United States Multicenter Cohort: Site- and Risk-Stratified Trends and Survival

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading